Overview
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Description
Calciphylaxis is a rare, devastating disorder causing excruciatingly painful ischemic skin lesions. Sepsis due to the infection of ulcerated wounds is a common cause of death. To date, practical therapies typically include wound care, pain management, anti-infection, anticoagulant and aggressive treatment of predisposing conditions. Drugs such as sodium thiosulfate(STS), bisphosphonate, SNF472 and cinacalcet are also suggested. However, it's still a lethal disease with 1-year mortality up to 80% for dialysis patients. Here the investigators plan to treat calciphylaxis patients with human amniotic-derived mesenchymal stem cells (hAMSCs).
Eligibility
Inclusion Criteria:
- 18-75 years old.
- Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).
- All subjects signed informed consent.
Exclusion criteria:
- Patients who refuse to sign informed consent.
- Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.
- Pregnant or lactating women of childbearing age.
- Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.
